This inventor holds 1 USPTO granted patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Damjana Rozman: Innovator in Cholesterol Biosynthesis Inhibition
Introduction
Damjana Rozman is a notable inventor based in Ljubljana, Slovenia. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit cholesterol biosynthesis. Her work is crucial for addressing health issues related to hypercholesterolemia and hyperlipemia.
Latest Patents
Rozman holds a patent for "Derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing them." This patent describes novel derivatives of pyridilethanol amines that serve as ligands for sigma receptors, effectively inhibiting cholesterol biosynthesis. The most effective compound identified in her research is 1-(d-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-propylamino)ethanol in the form of dihydrobromide salt (signature BK-35, 2HBr), which has shown significant cholesterol-lowering effects.
Career Highlights
Damjana Rozman is associated with Lek Pharmaceuticals D.d., a prominent pharmaceutical company in Slovenia. Her work at Lek Pharmaceuticals has allowed her to focus on innovative solutions for cholesterol-related health issues.
Collaborations
Rozman has collaborated with notable colleagues, including Klementina Fon Tacer and Darko Kocjan. These collaborations have contributed to the advancement of her research and the development of effective pharmaceutical compositions.
Conclusion
Damjana Rozman's innovative work in the field of cholesterol biosynthesis inhibition highlights her significant contributions to pharmaceutical sciences. Her patented compounds offer promising solutions for managing cholesterol levels in humans.